Paper6583205
4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors.
Schütte J and 5 others. J Cancer Res Clin Oncol, 1984. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. 4'-Epi-Doxorubicin -- a clinical phase-II trial in solid tumors. Papers, record 6583205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6583205
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Lung Neoplasms | Major topic |
| Adult | |
| Aged | |
| Alopecia | |
| Drug Evaluation | |
| Epirubicin | |
| Female | |
| Humans | |
| Kidney Neoplasms | |
| Leukopenia | |
| Male | |
| Middle Aged | |
| Nausea | |
| Testicular Neoplasms | |
| Thrombocytopenia |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7318126 | A phase of I trial of 4'-epi-Adriamycin. | Cancer Clin Trials | 1981 | https://conductscience.org/library/papers/7318126 | PubMed |
| 2 | 455333 | Preliminary phase I study of 4'-epi-adriamycin. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/455333 | PubMed |
| 3 | 6572190 | Phase II trial of aclacinomycin A in acute leukemia and various solid tumors. | J Cancer Res Clin Oncol | 1983 | https://conductscience.org/library/papers/6572190 | PubMed |
| 4 | 6952962 | Phase II study of 4'-epi-doxorubicin in metastatic renal cancer. | Cancer Treat Rep | 1982 | https://conductscience.org/library/papers/6952962 | PubMed |
| 5 | 455325 | Experimental evaluation of anthracycline analogs. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/455325 | PubMed |
| 6 | 6342772 | 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. | Cancer Treat Rev | 1983 | https://conductscience.org/library/papers/6342772 | PubMed |
| 7 | 6940313 | Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4'-epi-doxorubicin in guinea pig heart muscle. | Tumori | 1980 | https://conductscience.org/library/papers/6940313 | PubMed |
| 8 | 168385 | Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. | J Med Chem | 1975 | https://conductscience.org/library/papers/168385 | PubMed |
| 9 | 7296552 | Effect of 4'-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice. | Cancer Treat Rep | 1981 | https://conductscience.org/library/papers/7296552 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 1964677 | 4'-EPI-doxorubicin in advanced lung cancer. A phase II trial. | Invest New Drugs | 1990 | https://conductscience.org/library/papers/1964677 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6583205
GET https://conductscience.org/api/papers/v1/6583205/authors